Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vivalis, BioDiem's French partner, has reportedly grown BioDiem's Live Attenuated Influenza Virus (LAIV) BioDiem in its proprietary EB66 cell line, as part of the collaboration between the two companies.
Subscribe to our email newsletter
The companies will now use known techniques to demonstrate the creation of new, ‘disarmed’ viruses (vectors) that carry foreign antigens, which can be customized to fight specific diseases to advance the programme into next stage.
BioDiem CEO Julie Phillips said, "BioDiem is excited about the use of our in-house viral technology to establish a platform for new vaccine creation via the vector project."
Vivalis CEO Franck Grimaud and Vivalis CSO Majid Mehtali said, "We are focused on moving EB66® into exciting new indications, such as the therapeutic and preventative vaccines potentially offered by BioDiem’s LAIV technology."
The next step of the programme will be the development of a stable LAIV vector technology that uses EB66 as a base platform for growth.
Vivalis has undertaken the research based on the value of BioDiem’s technology in non-influenza vaccine applications, both therapeutic and preventative.